GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regulus Therapeutics Inc (STU:7RG0) » Definitions » Institutional Ownership

Regulus Therapeutics (STU:7RG0) Institutional Ownership : 29.02% (As of May. 16, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Regulus Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Regulus Therapeutics's institutional ownership is 29.02%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Regulus Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Regulus Therapeutics's Float Percentage Of Total Shares Outstanding is 93.08%.


Regulus Therapeutics Institutional Ownership Historical Data

The historical data trend for Regulus Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regulus Therapeutics Institutional Ownership Chart

Regulus Therapeutics Historical Data

The historical data trend for Regulus Therapeutics can be seen below:

2023-05-31 2023-06-30 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 79.83 90.63 90.04 90.34 89.54 89.54 90.89 92.55 93.93 29.02

Regulus Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Regulus Therapeutics (STU:7RG0) Business Description

Traded in Other Exchanges
Address
4224 Campus Point Court, Suite 210, San Diego, CA, USA, 92121
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.

Regulus Therapeutics (STU:7RG0) Headlines

No Headlines